ACRS•benzinga•
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments
Summary
Aclaris secures global rights to Biosion's BSI-045B, advancing trials for atopic dermatitis, asthma, and more. Stock surges on promising updates.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 19, 2024 by benzinga